Positive High-level Results from POTOMAC Phase III Trial in Patients With High-risk NMIBC
Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared a post on LinkedIn:
“This post is intended for a US audience.
AstraZeneca has just announced positive high-level results of the POTOMAC Phase III trial for high-risk, non-muscle-invasive bladder cancer (NMIBC). Over 70% of bladdercancer patients face NMIBC with around half considered at high risk for disease progression.
But patients on our medicine, plus standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, demonstrated a statistically significant and clinically meaningful improvement in disease-free survival compared to BCG induction and maintenance therapy alone.
We’re pushing the boundaries in bladder cancer, with powerful new options for patients in the earlier stages when the disease is more treatable. We’re eagerly awaiting the full trial results, which we’ll share at an upcoming medical conference.
Read the press release to learn more.”
More posts featuring Mohit Manrao.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023